GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

GoodRx works closely with Pharmacy Benefit Managers, more commonly called PBMs. PBMs are companies that manage prescription drug benefits on behalf of health insurers and others, according to ...